Weak evidence suggests Botulinum Toxin Type A may improve some outcomes in cerebral palsy
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.Cochrane Database Syst Rev. 2019. DOI: 10.1002/14651858.CD001408.pub2
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Cerebral palsy is a common childhood condition, with spasticity being one of its most disabling complications. Botulinum Toxin has long been used as first line treatment. The authors performed a Cochrane review of all randomized controlled trials comparing Botulinum Toxin to placebo or an active comparator. Overall, 31 trials randomized 1508 patients. The overall quality of the evidence was low or...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE